Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti

At Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, a major focus is non-small cell lung cancer and small cell lung cancer, with studies also covering EGFR- and KRAS-driven disease. These trials are designed to test new treatment combinations, compare them with current standards, and improve outcomes for people with advanced or recurrent lung cancer.

• Advanced and metastatic non-small cell lung cancer
• Small cell lung cancer in limited-stage and extensive-stage settings
• Research on targeted and immune-based therapies for EGFR and KRAS G12C mutations
• Studies aiming to improve survival and disease control after surgery or chemoradiotherapy

The site’s Medical Oncology team is especially active in evaluating whether newer approaches can work better than existing treatment options for lung cancer.

This site conducts clinical research in breast cancer and ovarian cancer, including both early and advanced disease. The studies explore new ways to strengthen standard treatment, reduce recurrence risk, and improve long-term disease control for patients facing hormone receptor-positive, HER2-positive, or high-risk cancers.

• Breast cancer, including high-risk, early-stage, and metastatic forms
• Ovarian cancer, especially advanced epithelial disease
• Trials focused on improving survival, preventing relapse, and supporting treatment effectiveness
• Evaluation of novel combinations for patients with difficult-to-treat gynecologic and breast tumors

Research at Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti also includes efforts to refine care for patients whose cancers have already received standard treatment.

The trial portfolio includes important work in gastric cancer, gastroesophageal junction adenocarcinoma, colorectal cancer, and hepatocellular carcinoma. These studies are generally aimed at testing whether new therapies or combinations can better control advanced disease and extend survival.

• Gastric cancer and gastroesophageal junction adenocarcinoma
• Colorectal cancer and metastatic solid tumors
• Hepatocellular carcinoma and other advanced abdominal cancers
• Trials assessing treatment benefit in previously treated or newly diagnosed patients

These studies reflect a broader effort to improve options for advanced gastrointestinal cancers where standard therapies may have limited benefit.

The site is also active in melanoma and other skin and connective tissue diseases, with trials covering both unresectable and resected disease. The main goal is to evaluate new immunotherapy-based approaches and determine whether they can improve survival and reduce the chance of relapse.

• Melanoma, including advanced, metastatic, and resected stages
• Studies in skin and connective tissue cancer-related conditions
• Testing new immune-based treatment strategies
• Research focused on recurrence prevention and long-term disease control

This research area supports more personalized treatment options for patients with aggressive melanoma and related cancers.

Clinical trials at the Bucharest site include head and neck squamous cell carcinoma, glioma, and other advanced solid tumors. The research is centered on improving response rates, supporting survival, and exploring new combinations for cancers that are often hard to treat.

• Head and neck squamous cell carcinoma, including locally advanced disease
• Glioma and other central nervous system-related cancers
• Solid tumors with limited treatment options
• Studies looking at better disease control and post-treatment outcomes

The Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti contributes to research aimed at expanding treatment choices for complex cancers beyond the most common tumor types.

Beyond direct cancer treatment, the site also studies complications linked to therapy, including chemotherapy-induced thrombocytopenia and chemotherapy-induced nausea and vomiting. These trials are designed to improve tolerability, help patients stay on treatment, and make cancer care safer and more manageable.

• Chemotherapy-induced thrombocytopenia in patients with lung, ovarian, or breast cancer
• Chemotherapy-induced nausea and vomiting prevention in pediatric cancer care
• Supportive care strategies to maintain treatment continuity
• Research aimed at reducing side effects and improving quality of care

These studies show that the site’s clinical research extends beyond tumor control to include practical ways of helping patients better tolerate cancer therapy.